https://www.selleckchem.com/pr....oducts/qnz-evp4593.h
Mortality risk increased significantly across groups 1.34% in the low-risk group (score 0-58), 5.40% in intermediate group (score 59-93), and 23.87% in high-risk group (score ≥94). The current study established and validated a practical risk score based on 9 variables to predict 24-month mortality risk in patients who survive NSTEMI. This score could help identify patients who are at high risk for future adverse events who may benefit from good adherence to guideline-recommended secondary prevention treatment. The current study esta
Like
Comment
Share
